Notably, consistent with our previous observations showing that ACVR2B/Fc potently counteracts chemotherapy‐induced bone loss,22 inhibition of ACVR2B was able to completely preserve cancellous bone measurements in tumour hosts, as suggested by augmented BV/TV (+124%, P < 0.0001), Tb.N (+117%, P < 0.0001), and Conn.Dn (+111%, P < 0.001), as well as by decreased Tb.Sp (−52%, P < 0.05) and Tb.Pf (−47%, P < 0.0001) (Figure6A–6F). This evidence concerns the gene ACVR2B and neoplasm.